GlassScriptPhysician profile
Todd A Kupferman
NPI 1356371041
$2,622.39
in general payments reported to CMS, 2019-2025
14 companies · $785 in 2025
The $785 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $228 · 2021: $425 · 2022: $630 · 2023: $104 · 2024: $335 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,338.59 | 2019-2025 | Scopis Ent, Audion Et Dilation System, Xpress Ent Dilation System |
| Medtronic, INC. | $381.63 | 2024-2025 | Propel |
| Optinose US, INC. | $197.99 | 2019-2024 | |
| Neurent Medical Limited | $152.14 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Kaleo, INC. | $107.24 | 2019-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $102.25 | 2025 | Neffy |
| Genzyme Corporation | $92.56 | 2020-2022 | |
| Smith+Nephew, INC. | $90.76 | 2020 | |
| Alk-Abello, INC | $45.32 | 2020 | |
| Pfizer INC. | $35.00 | 2022 | |
| Aerin Medical INC. | $26.95 | 2020 | |
| Phathom Pharmaceuticals, INC. | $21.64 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $16.77 | 2022 | |
| Biocryst US Sales Co., LLC | $13.55 | 2025 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Kupferman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.